See more : Compass Digital Acquisition Corp. (CDAQU) Income Statement Analysis – Financial Results
Complete financial analysis of Calliditas Therapeutics AB (publ) (CALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Adani Energy Solutions Limited (ADANIENSOL.BO) Income Statement Analysis – Financial Results
- Australian Agricultural Projects Ltd (AAP.AX) Income Statement Analysis – Financial Results
- Hextar Global Berhad (5151.KL) Income Statement Analysis – Financial Results
- Jess-link Products Co., Ltd. (6197.TW) Income Statement Analysis – Financial Results
- Johns Lyng Group Limited (JLG.AX) Income Statement Analysis – Financial Results
Calliditas Therapeutics AB (publ) (CALT)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 802.88M | 229.35M | 874.00K | 184.83M | 0.00 | 0.00 | 497.00K | 478.00K |
| Cost of Revenue | 77.06M | 15.20M | 0.00 | 0.00 | 0.00 | 51.00K | 51.00K | 56.52M | 51.39M |
| Gross Profit | 1.13B | 787.68M | 229.35M | 874.00K | 184.83M | -51.00K | -51.00K | -56.02M | -50.91M |
| Gross Profit Ratio | 93.62% | 98.11% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Research & Development | 499.54M | 414.75M | 357.49M | 241.37M | 149.83M | 99.26M | 384.00K | 40.28M | 36.89M |
| General & Administrative | 332.99M | 259.47M | 210.63M | 102.76M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Selling & Marketing | 727.74M | 515.19M | 179.60M | 38.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.01B | 774.66M | 390.23M | 141.72M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Other Expenses | 0.00 | 20.21M | 6.09M | 0.00 | 0.00 | 51.00K | 51.00K | 112.00K | 111.00K |
| Operating Expenses | 1.51B | 1.21B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Cost & Expenses | 1.59B | 1.22B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Interest Income | 29.10M | 50.20M | 102.00K | 547.00K | 926.00K | 6.00K | 0.00 | 2.00K | 0.00 |
| Interest Expense | 73.20M | 12.53M | 7.11M | 393.00K | 325.00K | 8.00K | 2.24M | 1.01M | 9.00K |
| Depreciation & Amortization | 16.59M | 12.91M | 34.43M | 2.82M | 1.82M | 51.00K | 51.00K | 112.00K | 111.00K |
| EBITDA | -367.80M | -388.82M | -483.94M | -379.40M | -25.13M | -133.14M | -84.60M | -56.40M | -51.28M |
| EBITDA Ratio | -30.48% | -52.55% | -228.67% | -43,346.80% | -13.60% | 0.00% | 0.00% | -11,348.69% | -10,727.62% |
| Operating Income | -384.40M | -421.94M | -524.46M | -379.72M | -28.02M | -132.48M | -84.51M | -56.02M | -50.91M |
| Operating Income Ratio | -31.85% | -52.55% | -228.67% | -43,446.22% | -15.16% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Total Other Income/Expenses | -72.62M | 5.39M | 9.47M | -53.93M | -4.48M | 1.15M | -2.29M | -395.00K | 375.00K |
| Income Before Tax | -457.02M | -409.42M | -513.37M | -436.15M | -32.50M | -132.05M | -86.79M | -56.91M | -51.01M |
| Income Before Tax Ratio | -37.87% | -50.99% | -223.84% | -49,902.86% | -17.58% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| Income Tax Expense | 9.17M | 2.85M | -3.84M | 360.00K | 77.00K | 441.00K | 2.24M | 1.01M | 9.00K |
| Net Income | -466.19M | -412.27M | -509.54M | -436.51M | -32.58M | -132.05M | -86.79M | -56.91M | -51.01M |
| Net Income Ratio | -38.63% | -51.35% | -222.17% | -49,944.05% | -17.63% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| EPS | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| EPS Diluted | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| Weighted Avg Shares Out | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
| Weighted Avg Shares Out (Dil) | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
Calliditas promotes Andrew Udell to President, North America
STOCKHOLM, May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commercial, Andrew Udell, has been promoted to President, North America, effective immediately. "Andrew has been instrumental in the growth...
Calliditas Therapeutics AB: Change in financial calendar
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first quarter 2021 will be published on May 18, 2021. The previously planned...
Calliditas Therapeutics' 2020 Annual Report Published
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: www.calliditas.com. This information is information that Calliditas Therapeutics AB is obliged to...
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM, April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on Thursday 27 May 2021.
Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease
Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (IgAN). IgAN, also known as Berger's disease, is a kidney disease that occurs when an antibody called...
4 Undervalued Stocks That Could Rip Higher
Undervalued stocks that are likely to surge higher in the next few quarters supported by company specific catalysts and industry tailwinds. The post 4 Undervalued Stocks That Could Rip Higher appeared first on InvestorPlace.
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial
STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon® versus...
Calliditas Therapeutics' nomination committee for the AGM 2021
STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14,...
Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck...
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report
STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also host a telephone conference, which will include a presentation of...
Source: https://incomestatements.info
Category: Stock Reports